Regeneron Posts 17% Revenue Growth and Raises 2026 Profitability Guidance

Regeneron reported second-quarter 2026 revenue of $4.291 billion, up 17% from $3.676 billion a year earlier, while GAAP diluted EPS was $12.23 and non-GAAP diluted EPS was $14.29. Dupixent sales reached $6.0 billion globally, EYLEA HD U.S. sales rose 52% to $596 million, and Libtayo global sales increased 30% to $489 million; the company also fully repaid its Sanofi Development Balance, which it expects will increase collaboration revenue beginning in the third quarter. Regeneron updated its 2026 guidance to lower ranges for R&D, SG&A, and capital expenditures while raising its expected GAAP and non-GAAP gross margins and effective tax rates; it declared a $0.94 dividend payable August 31, 2026, to shareholders of record August 18.